TRACON Pharmaceutical (TCON) Prices 2.625M Share Common Stock Offering for Proceeds of ~$15.1M
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
TRACON Pharmaceuticals Announces Pricing of Public Offering of Common Stock
November 23, 2016 8:54 AM ESTSAN DIEGO, Nov. 23, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), today announced the pricing of an underwritten public offering of 2,625,000 shares of its common stock at a price to the public of $5.75 per share. The gross proceeds to TRACON from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $15.1 million. The offering is expected to close on or about November 29, 2016, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 393,750... More
TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City
November 22, 2016 7:05 PM ESTSAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that it will host a Key Opinion Leader luncheon for investors focused on the treatment of angiosarcoma and metastatic castration-resistant prostate cancer (mCRPC) at 12:00pm Eastern Time on Thursday, December 1, 2016.
This meeting will feature keynote presentations by key opinion leaders Mrinal M. Gounder, M.D., from Memorial Sloan Kettering Cancer... More
TRACON Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 22, 2016 4:01 PM ESTSAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are being sold by TRACON. In addition, TRACON expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or... More